Capricor Therapeutics (CAPR): Tracking the Path to the November FDA Decision
Key Takeaways
- Capricor Therapeutics (CAPR) is a clinical-stage biotech whose near-term outlook is dominated by the U.S. FDA review of its lead candidate, Deramiocel, for Duchenne muscular dystrophy (DMD).
- Over roughly the past 30 days, the stock has traded in a range without a sustained double-digit move, reflecting a balance between recent analyst upgrades and lingering regulatory and legal uncertainty.
- The FDA extended the review timeline for Deramiocel to November 22, 2026, which several analysts framed as a window for additional data or regulatory clarity.
- Analyst sentiment has turned more constructive, with upgrades from Piper Sandler, B. Riley, and Oppenheimer despite the stock's sharp decline in July 2026.
- Outstanding securities class actions tied to the HOPE-3 trial's statistical analysis plan remain a key overhang on investor sentiment.
Where the Stock Stands Today
Capricor Therapeutics has remained in the single digits as the market weighs competing signals around its lead asset. Following a steep selloff in late July 2026, the stock stabilized and has since traded largely sideways, with day-to-day moves driven by analyst actions and regulatory headlines rather than a single directional catalyst. The shares have shown meaningful volatility over the past year, and their current level sits well below the 52-week high reached before FDA briefing documents raised questions about the HOPE-3 trial analysis. With limited commercial revenue to date, valuation continues to hinge on expectations for future Deramiocel approval and commercialization rather than current financial results. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Capricor Therapeutics (CAPR) Business Overview and Competitive Position
Capricor Therapeutics is a San Diego-based biotechnology company developing cell and exosome-based therapies for rare diseases with high unmet medical need. Its lead product candidate, Deramiocel (also referred to as CAP-1002), is an allogeneic cardiosphere-derived cell (CDC) therapy being developed for the treatment of Duchenne muscular dystrophy. The clinical program has focused primarily on adolescents and young adults with DMD, including many non-ambulatory patients experiencing progressive cardiac and skeletal muscle decline. The company is also advancing a StealthX exosome platform designed for vaccine and therapeutic applications. As a clinical-stage developer without meaningful product sales, Capricor is evaluated primarily on clinical data, regulatory progress, and its cash runway rather than conventional earnings metrics.
Recent Developments Driving the Stock
Regulatory news has been the central driver of Capricor's share price. In late July 2026, the release of FDA briefing documents ahead of an advisory committee meeting triggered a sharp single-session decline, as the agency characterized certain analyses of the Phase 3 HOPE-3 trial as post-hoc and exploratory and an advisory committee voted against efficacy support. The stock has since been working through the consequences of that disclosure.
In September 2026, sentiment shifted as the FDA extended the action date for the Deramiocel biologics license application to November 22, 2026. Analysts interpreted the extension as a potential opportunity for the company to submit additional data or secure further regulatory clarity. Piper Sandler upgraded the stock to Overweight with a price target of $25, B. Riley moved to Buy with a $21 target, and Oppenheimer raised its view to Outperform with a $54 target. These upgrades reflected a more optimistic read on the risk-reward profile heading into the extended review period.
Offsetting that optimism, several law firms announced securities class actions alleging that the company did not follow the pre-specified blinding and protocol procedures for HOPE-3 and that investors were not informed of deviations between the final statistical analysis plan and the trial protocol. This litigation remains an ongoing source of uncertainty.
2026 Outlook and Key Factors to Monitor
The defining event for Capricor in 2026 is the FDA's decision on Deramiocel, now expected on November 22, 2026. The outcome will determine whether the company can transition from a clinical-stage developer toward a commercial-stage cell therapy provider, and it will materially reshape the investment thesis in either direction. From what I see, this remains the single most important catalyst on the horizon.
Beyond the regulatory decision, investors should monitor several factors. Any additional data submissions or communications with the FDA ahead of the action date could influence sentiment. The company's cash position, reported at roughly $237.9 million as of June 30, 2026, provides runway but remains a key metric as research and development and general and administrative expenses continue to rise. The progress of the StealthX exosome platform and any international regulatory or partnership activity for Deramiocel also carry longer-term relevance. Finally, the outcome of the securities class actions and analyst target revisions could continue to drive short-term volatility. As with all clinical-stage biotechnology investments, the potential for a binary regulatory outcome means the risk profile is elevated. I’m watching this closely as the November deadline approaches.
Exploring AI-Driven Trading Approaches
One tool I’ve found helpful for tracking biotech names like this is Tickeron’s Trending AI Robots. It surfaces top-performing automated strategies across thousands of tickers, allowing users to review how algorithm-driven approaches are performing in the current market environment. This gives an additional perspective alongside traditional fundamental research without replacing it.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CAPR in -3.58% downward trend, declining for three consecutive days on September 25, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CAPR declined for three days, in 249 of 299 cases, the price declined further within the following month. The odds of a continued downward trend are 83%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Momentum Indicator moved above the 0 level on September 29, 2026. You may want to consider a long position or call options on CAPR as a result. In 72 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
CAPR moved above its 50-day moving average on September 28, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CAPR crossed bullishly above the 50-day moving average on September 25, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +6.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAPR advanced for three days, in 228 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 138 of 168 cases where CAPR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. CAPR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.057) is normal, around the industry mean (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (7.610) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (125.000) is also within normal values, averaging (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 91 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CAPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Develops innovative products for the treatment of cardiovascular diseases
Industry Biotechnology